Linifanib

Target: This ligand targets VEGFR and PDGFR receptor tyrosine kinases in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for VEGFR and PDGFR receptor tyrosine kinases. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings VEGFR into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• Kinase-Targeted PROTAC Design: Linifanib can serve as a kinase-binding ligand to construct PROTACs aimed at degrading specific tyrosine kinases implicated in oncogenic signaling. By coupling Linifanib to an E3 ligase recruiter, researchers can test whether ternary complex formation drives ubiquitination and proteasome-dependent removal of the intended kinase in cellular degradation assays.

• Pathway-Driven Degradation Studies: Use Linifanib-based PROTACs to interrogate how sustained loss of kinase activity reshapes downstream phosphorylation networks. These constructs enable time-resolved monitoring of target depletion, signaling collapse, and compensatory pathway activation, supporting mechanistic studies on kinase dependency and resistance phenotypes in PROTAC-treated models.

• Selectivity and Off-Target Profiling: Linifanib’s kinase engagement profile can be leveraged to evaluate PROTAC selectivity across related family members. Researchers can compare degradation potency and kinetics among candidate kinases, using proteomics and immunoblotting to distinguish on-target degradation from off-target effects, and to guide ligand optimization for improved specificity.

• E3 Ligase Recruitment Optimization: Linifanib-derived PROTACs can be paired with different E3 ligase ligands to determine which ubiquitination machinery yields robust target degradation. Systematic variation of linker length and recruiter identity can reveal structure–activity relationships governing ternary complex stability and degradation efficiency in target engagement and washout experiments.

Linifanib is a kinase inhibitor scaffold that can be considered for receptor tyrosine kinase-directed PROTAC research. Its urea-linked heteroaryl core should be retained during linker-vector optimization.

Structure: Linifanib is a kinase inhibitor scaffold featuring a urea-linked indazole/indazole-like heteroaryl system and a fluorinated aryl group. The structure contains multiple hydrogen-bond donors and acceptors, aromatic hydrophobic surfaces, and halogenated substituents that contribute to kinase recognition.

Reactivity: Linifanib-derived PROTAC design should preserve the urea and heteroaryl pharmacophore required for kinase binding. Linker attachment is most plausibly introduced through solvent-exposed aryl or heteroaryl substituent analogs rather than direct modification of the urea core. Alkyl, PEG, amide, carbamate, or aryl-linker vectors can be paired with CRBN, VHL, or IAP ligands after confirming that the selected vector does not disrupt target engagement.